Please assess the completion status of the following clinical trial:

Trial Title: ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting in the participating hospitals with a TIA or non-disabling stroke of atherosclerotic origin~* Randomisation within 6 months after the TIA or minor stroke~* Modified Rankin scale of 3 or less~Exclusion Criteria:~* (Contra)indication to, or intolerance to, anticoagulants, dipyridamole, or aspirin~* Disease expected to cause death within weeks or months~* Source of embolism in the heart~* Moderate or severe ischemic damage to the white matter of the brain (leukoaraiosis)~* Anemia, polycythemia, thrombocytosis, or thrombocytopenia~* Planned carotid endarterectomy~* Intracranial bleeding or cerebral tumour~* TIA or stroke caused by vasculitis, migraine, or dissection~* Severe hypertension~* Liver failure~* Pregnancy~* Chronic alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).